Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (109)
  3. Review (18)
  4. Research Letter (14)
  5. Editorial (6)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (371)
  2. Center for Hematologic Malignancies (371)
  3. Department of Medicine (371)
  4. Hematologic Malignancies, Division of (371)
  5. Hematology-Oncology Fellows (111)
  6. GSK Faculty (92)

More Groups

People
  1. Martin Tallman (118)
  2. Ross Levine (75)
  3. Aaron Goldberg (43)
  4. Andriy Derkach (33)
  5. Jan Bewersdorf (33)
  6. Christopher Famulare (31)

More People

Years
  1. 2025 (20)
  2. 2024 (45)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (171)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (18)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (186)
  2. Elsevier Inc. (32)
  3. American Society of Clinical Oncology (28)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (371)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) with missing molecular data
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • KB-Lanra 1001: A phase 1b/2 study of safety, PK, PD, and preliminary efficacy of the selective SYK inhibitor lanraplenib in combination with the FLT3 inhibitor gilteritinib in FLT3-mutated R/R AML
    Meeting Abstract

    Arnan, M.; Patel, A. A.; Esteve, J.; Morris, L.; Schiller, G. J.; Swords, R. T.; Alonso-Dominguez, J. M.; Michaelis, L. C.; Daver, N.; Carvajal, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Validation of the Molecular International Prognostic Scoring System (IPSS-M) in patients (pts) with myelodysplastic syndromes/neoplasms (MDS) who were treated with hypomethylating agents (HMA)
    Meeting Abstract

    Kewan, T.; Bewersdorf, J. P.; Blaha, O.; Stahl, M.; Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Carraway, H. E.; Desai, P.; Griffiths, E. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Beat AML S8 Group 2: Gilteritinib (GILT) in combination with decitabine (DEC) and venetoclax (VEN) in untreated FLT3 mutated acute myeloid leukemia (AML) patients age ≥60 with high and low variant allele frequency (VAF)
    Meeting Abstract

    Liu, Q.; Welkie, R. L.; Huang, Y.; Swords, R. T.; Lin, T. L.; Koenig, K. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; Blum, W.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Revumenib maintenance therapy following revumenib-induced remission and transplant
    Meeting Abstract

    Zucenka, A.; Issa, G. C.; Arellano, M.; Khazal, S.; Khera, N.; Stock, W.; Cuglievan, B.; Gu, Y.; Nguyen, H. V.; Smith, A. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Preliminary results from a phase 1 dose escalation study of FHD-286, a novel BRG1/BRM (SMARCA4/SMARCA2) inhibitor, administered as an oral monotherapy in patients with advanced hematologic malignancies
    Meeting Abstract

    DiNardo, C. D.; Savona, M. R.; Kishtagari, A.; Fathi, A. T.; Bhalla, K. N.; Agresta, S.; Reilly, S.; Almon, C.; Hentemann, M.; Hickman, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Ivosidenib for patients with clonal cytopenia of undetermined significance and mutations in IDH1
    Meeting Abstract

    Petrone, G.; Stein, E. M.; Bolton, K. L.
    Blood (2023)

    Fulltext@MSK | Save
  • A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M.; Rampal, R. K.; Bose, P.
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Venetoclax in combination with pediatric-inspired chemotherapy in adults with newly diagnosed acute lymphoblastic leukemia: Results of a phase I trial
    Meeting Abstract

    Valtis, Y. K.; Geyer, M. B.; Torres, M.; Grogan, M.; Shukla, M.; Stein, E. M.; Park, J. H.
    Blood (2023)

    Fulltext@MSK | Save